Navigation Links
Neuralstem Reports First Quarter Financial Results And Provides Business And Clinical Update
Date:5/10/2013

rain injury. These injuries can result in long-term and serious loss of cognitive function, depression, a shorter life span and, as has been reported in some high-profile NFL cases, death by suicide.

Corporate News:

In April, Neuralstem received notice of allowance for patent application 12/404,841, which covers methods of treatment of ALS with expanded spinal cord stem cells, including NSI-566.

First Quarter Financial ResultsFor the first quarter of 2013, the Company reported a net loss of approximately $3,590,000 or $0.05 per share, compared with a net loss of approximately $2,453,000 or $0.05 per share, for the comparable 2012 period.  The increase in net loss was primarily due to a non-cash charge of approximately $667,000 related to the modification of certain stock purchase warrants coupled with an approximately $125,000 increase in project and lab expenses related to ramping up of our clinical trial and research efforts and an increase in non-cash stock based compensation expense of approximately $107,000.  In addition, in the first quarter of 2013, the Company recognized approximately $103,000 in revenue from third party licensing of certain intellectual properties.

Total cash and cash equivalents on hand at March 31, 2013 totaled approximately $12,659,000 compared to approximately $7,444,000 at December 31, 2012.  The increase in our cash and cash equivalents of approximately $5,215,000 was primarily due to proceeds from our debt financing transaction completed in the first quarter partially offset by cash used in our operations.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem completed an FDA-approved Phase I safety clinical trial for amyotro
'/>"/>

SOURCE Neuralstem, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
2. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
3. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
4. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
5. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
6. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
7. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
8. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
9. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
10. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
11. Inovio Pharmaceuticals Reports 2013 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 The changing healthcare landscape ... involving clinical development, regulatory compliance and market education. ... Medical Affairs has faced many challenges in creating ... And while its importance is recognized internally, Medical ... strong performance metrics to demonstrate the value of ...
(Date:5/29/2015)... , May 29, 2015 In recent years, ... availability of Big Data that can generate valuable insights. ... with utilizing Big Data have caused the biopharmaceutical sector ... industries. According to a recent study ... already have a Big Data team or function in ...
(Date:5/29/2015)... 29, 2015 BerGenBio AS ("BerGenBio" ... that an abstract on the latest data on BGB324, ... Axl receptor tyrosine kinase, and BGB10C9, an Axl function-blocking ... published in conjunction with the 2015 American Society of ... , May 29 - June 2, 2015. ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 ... multi-drug-resistant organisms (MDROs), announced that initial feasibility data ... bacterial detection and susceptibility testing from positive blood ... on May 31, 2015 in New Orleans, LA. ... of molecular diagnostics that can quickly detect bacteria ...
Breaking Biology Technology:Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3
... N.Y. , July 29 On ... Publication Professionals (ISMPP) and the Medical Publishing Insights and ... various MPIP initiatives ( http://www.mpip-initiative.org ). The web page ... MPIP initiative, updating viewers on new or planned activities, ...
... , Saliva-Based DNA Collection Product Chosen for Study to Identify ... , , ... /PRNewswire/ - DNA Genotek, a leading provider of products ... the world,s leading TB vaccine research site, the South African ...
... , VANCOUVER , July 28 ... ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) ... trial of MultiStem(R), its allogeneic cell therapy product, ... more commonly referred to as a heart attack. ...
Cached Biology Technology:ISMPP and MPIP Announce New Medical Publishing Website 2ISMPP and MPIP Announce New Medical Publishing Website 3DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 2DNA Genotek's Oragene-DNA Achieves 95% Compliance Rate in South African Tuberculosis Vaccine Initiative (SATVI) 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 2Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 3Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 4Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 5Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 6Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 7Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 8Angiotech Pharmaceuticals and partner Athersys announce positive results from phase I study of MultiStem(R) in heart attack patients 9
(Date:5/29/2015)... DUBLIN , May 28, 2015 ... the addition of the "Facial Recognition Market ... User - Global Forecast to 2020" report ... years, have seen facial recognition technology become more ... technology to gain traction and investment from the ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... Goldfarb LLP is investigating whether the board of ... shareholder protection laws as evidenced through alleged inconsistencies in ... stock before June 15, 2012 are encouraged to contact ... about their rights and remedies. "On ...
... Athens, Ga. University of Georgia scientists have discovered ... the immune system. Kimberly Klonowski, assistant professor of cellular ... Sciences, and her colleagues found that administering a cell-signaling ... reduces their peak viral load by nearly three times. ...
... Research Centre of Finland in collaboration with the University ... signature which predicts progression to Alzheimer,s disease months or ... occur. The goal of the new collaboration between VTT ... a large patient cohort as well as to discover ...
Cached Biology News:UGA study reveals flu-fighting role for well-known immune component 2VTT and GE Healthcare developing novel biomarkers to predict Alzheimer's disease 2